for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

142.38USD

Change

0.73(+0.52%)

Volume

882,765

Today's Range

141.90

 - 

144.69

52 Week Range

101.41

 - 

170.75

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
141.65
Open
142.00
Volume
882,765
3M AVG Volume
70.59
Today's High
144.69
Today's Low
141.90
52 Week High
170.75
52 Week Low
101.41
Shares Out (MIL)
956.47
Market Cap (MIL)
136,182.30
Forward P/E
--
Dividend (Yield %)
2.08

Next Event

Eli Lilly and Co Split For LLY.BA - Ratio 2-1

Latest Developments

More

Eli Lilly Says 1 Manufacturing Plant Underwent FDA General Surveillance Inspection Recently

Lilly Announces Agreement To Acquire Disarm Therapeutics

Lilly Statement On NIAID Decision To Pause Enrollment In Activ-3 Clinical Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eli Lilly And Co

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry

Biotechnology & Drugs

Contact Info

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

INDIANAPOLIS, IN

46285-0001

United States

+1.317.2762000

https://www.lilly.com/

Executive Leadership

David A. Ricks

Chairman of the Board, President, Chief Executive Officer

Joshua L. Smiley

Chief Financial Officer, Senior Vice President

Aarti Shah

Senior Vice President - Chief Information and Digital Officer

Daniel M. Skovronsky

Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories

Melissa Stapleton Barnes

Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Key Stats

2.32 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.9K

2018

24.6K

2019

22.3K

2020(E)

23.9K
EPS (USD)

2017

4.280

2018

5.550

2019

6.040

2020(E)

7.274
Price To Earnings (TTM)
23.16
Price To Sales (TTM)
5.93
Price To Book (MRQ)
33.27
Price To Cash Flow (TTM)
19.90
Total Debt To Equity (MRQ)
398.94
LT Debt To Equity (MRQ)
368.06
Return on Investment (TTM)
19.88
Return on Equity (TTM)
13.93

Latest News

Latest News

Lilly hires external adviser for COVID-19 drug plant problems

Eli Lilly and Co <LLY.N> said late on Tuesday it had hired an independent consultant to review a plant producing its COVID-19 antibody drug after receiving a notice from the U.S. health regulator.

Lilly hires outside advisor for COVID drug plant problems

Eli Lilly and Co said late on Tuesday it had hired an independent consultant to review a plant producing its promising COVID-19 drug after receiving notices from the U.S. health regulator.

World stocks pause rally on J&J news, dollar bounces from three-week low

The dollar rose from a three-week low on Tuesday while U.S. and European shares eased, as news of pauses in trials of a COVID-19 vaccine and a treatment led investors to take stock of recent rallies before chasing further gains.

Dollar strengthens as vaccine, stimulus hopes dim

The U.S. dollar strengthened on Tuesday as investors turned cautious after a Johnson & Johnson COVID-19 study was paused and as hopes dimmed that a fiscal stimulus package could be reached before the presidential election.

BRIEF-Eli Lilly Antibody Trial Is Paused Because Of Potential Safety Concern- NYT

* ELI LILLY ANTIBODY TRIAL IS PAUSED BECAUSE OF POTENTIAL SAFETY- NYT REPORTER

U.S. expects over 1 million COVID-19 antibody doses from Regeneron, Lilly in 2020

The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.

Trump says he is pushing to get Regeneron's COVID-19 treatment approved quickly

U.S. President Donald Trump said on Friday he is working to get coronavirus antibody drugs developed by Regeneron Pharmaceuticals Inc and Eli Lilly and Co approved quickly and out to hospitals after his own positive coronavirus treatment experience.

Eli Lilly in deal to supply COVID-19 drugs to low-income countries

Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.

Eli Lilly signs deal for supply of COVID-19 treatments to low income countries

Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh...

Eli Lilly applies for emergency use of antibody drug for COVID-19

Eli Lilly and Co on Wednesday said it applied for U.S. emergency use authorization (EUA) for its experimental COVID-19 antibody treatment and plans to pursue a similar approval for a dual antibody therapy next month after it produced promising data.

Eli Lilly applies for FDA emergency use authorization for COVID-19 treatment

Eli Lilly and Co said on Wednesday it had submitted a request to the U.S. Food and Drug Administration for emergency use of its experimental antibody treatment for COVID-19.

Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo study

Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir.

Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients

Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.

BRIEF-Fauci Expects Results From ACTIV-2 Study On Lilly's Antibody Drug By Oct. Or Nov.

* NIH'S FAUCI SAYS EXPECTS RESULTS ON EFFECTIVENESS OF ELI LILLY'S ANITBODY TREATMENT IN MILD TO MODERATE COVID-19 FROM ACTIV-2 TRIAL BY OCT. OR EARLY NOV. Further company coverage:

BRIEF-Eli Lilly And Co Announced Full Results From EMPERIAL Exercise Ability Trials Presented

* ELI LILLY AND CO - FULL RESULTS FROM EMPERIAL EXERCISE ABILITY TRIALS PRESENTED

BRIEF-Eli Lilly's Emgality Showed Reduction In Frequency, Duration And Migraine Pain Severity

* EMGALITY® DEMONSTRATES REDUCTION IN FREQUENCY, DURATION, AND PAIN SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE

Lilly's breast cancer drug succeeds in study, shares rise 11%

Eli Lilly and Co said on Tuesday its treatment, Verzenio, met the trial goal of reducing the risk of early-stage breast cancer returning, sending the company's shares up 11%.

BRIEF-Eli Lilly Says Verzenio With Standard Adjuvant Endocrine Therapy Met Primary Endpoint Of Invasive Disease-Free Survival

* VERZENIO® (ABEMACICLIB) SIGNIFICANTLY REDUCED THE RISK OF CANCER RETURNING IN PEOPLE WITH HIGH RISK HR+, HER2- EARLY BREAST CANCER

Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients

Eli Lilly and Co on Monday said it was launching a study of its rheumatoid arthritis drug baricitinib in patients hospitalized for COVID-19.

Eli Lilly starts late-stage study of arthritis drug in COVID-19 patients

U.S. drugmaker Eli Lilly and Co said on Monday it has started a late-stage trial testing its rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up